不同单次高剂量丁丙诺啡减少急性抑郁共病阿片依赖者自杀意念的效果:一项随机双盲临床试验
本研究纳入51名符合DSM-5阿片依赖和重性抑郁障碍诊断的自杀男性住院患者,随机分为三组,分别接受单次舌下32mg、64mg或96mg丁丙诺啡。结果显示三组BSSI评分均显著下降(p<0.01),但组间无差异(p=0.408),提示单次高剂量丁丙诺啡可能快速治疗自杀意念。
要点
- 单次高剂量丁丙诺啡可显著降低共病阿片依赖的急性抑郁患者自杀意念评分。
- 32mg、64mg、96mg三种剂量降低自杀意念的效果无显著差异。
- 研究未设安慰剂组,需安慰剂对照试验评估安全性和生理心理效应。
核心结论
- 单次高剂量丁丙诺啡可能快速治疗自杀意念,或可作为阿片依赖患者快速治疗的主要机制药物。
研究设计与样本
- 随机双盲临床试验,纳入51名符合DSM-5阿片依赖和重性抑郁障碍诊断的自杀男性住院患者,随机分为三组(每组n=17),分别接受单次舌下32mg、64mg或96mg丁丙诺啡。
- 实际完成分析47人:32mg组16人(34.04%),64mg组17人(36.17%),96mg组14人(29.78%)。
- 未设安慰剂组,因无活性药物治疗时严重戒断可能性高;给药时患者处于中度阿片戒断状态(4-5个戒断症状)。
主要发现
- 三组BSSI评分均显著下降,p<0.01。
- 三组间结果无差异,p=0.408。
关键数值与推荐
- 采用Beck自杀意念量表(BSSI)和基于DSM-5标准的访谈进行评估。
临床怎么用
- 单次高剂量丁丙诺啡可能用于快速减少阿片依赖共病急性抑郁患者的自杀意念。
局限性
- 未设安慰剂组,无法排除安慰剂效应。
- 样本量较小(51人随机,47人分析),仅纳入男性住院患者。
- 需安慰剂对照试验评估安全性和生理心理效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Buprenorphine is usually administered to treat opioid use disorder and pain syndromes. This research presents the first study regarding the effectiveness of different singly administered high doses of buprenorphine (a partial opioid agonist (of μ-opioid receptors), a potent opioid antagonist (of κ-receptors) and a partial agonist of nociception receptors) in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence. It follows small studies that suggest that ultra-low-dose buprenorphine may be useful in reducing suicidal ideation. The goal of this study was to describe the outcome of different doses of buprenorphine on suicidal opioid-dependent patients over a 3-day interval, by conducting a randomized clinical trial. METHODS: Fifty-one suicidal male inpatients who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for both opioid dependence and major depressive disorder were randomized to three groups (n = 17 per group) to receive a single, sublingual dose of buprenorphine (32 mg, 64 mg, or 96 mg). Out of 51 participants, there were 47 patients; 16 (34.04%) received 32 mg, 17 (36.17%) received 64 mg, and 14 (29.78%) received 96 mg of sublingual buprenorphine. They were evaluated by using psychometric assessment of the Beck Scale for Suicidal Ideation (BSSI) and interviews based on DSM-5 criteria. A placebo group was not included because of the high probability of severe withdrawal without active pharmacological treatment. The study was conducted with appropriate precautions and monitoring of respiratory and cardiovascular measures. The medication was administered while the patients were in moderate opiate withdrawal, as indicated by the presence of four to five withdrawal symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed. RESULTS: Patients completed the 3-day trial course. The outcomes illustrated a significant reduction in BSSI scores within each of the three groups, p < 0.01., but no difference in results between the groups, p = 0.408. CONCLUSIONS: The results suggest that a single high dose of buprenorphine could rapidly treat suicidal ideations. A single high dose of buprenorphine may be a main-mechanism medication that gives a rapid treatment for suicidal opioid-dependent patients. Placebo-controlled trials are required to measure the safety and the physiological and psychological effects of this medication.
引用
- Ahmadi J, Jahromi MS, Ehsaei Z, et al. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials. 2018. PMID: 30157924. doi:10.1186/s13063-018-2843-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。